Viridian Therapeutics Inc
VRDN
Company Profile
Business description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Contact
221 Crescent Street
Suite 103A
WalthamMA02453
USAT: +1 617 272-4600
E: info@miragenrx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
143
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,510.70 | 0.00 | 0.00% |
| CAC 40 | 7,873.83 | 23.73 | 0.30% |
| DAX 40 | 23,638.56 | 72.02 | 0.31% |
| Dow JONES (US) | 42,140.43 | 269.67 | -0.64% |
| FTSE 100 | 8,602.92 | 2.06 | -0.02% |
| HKSE | 23,108.27 | 441.19 | -1.87% |
| NASDAQ | 19,010.09 | 301.74 | 1.61% |
| Nikkei 225 | 38,171.67 | 11.59 | -0.03% |
| NZX 50 Index | 12,797.54 | 10.80 | 0.08% |
| S&P 500 | 5,886.55 | 42.36 | 0.72% |
| S&P/ASX 200 | 8,264.90 | 4.10 | -0.05% |
| SSE Composite Index | 3,374.87 | 5.63 | 0.17% |